Federated Hermes Inc. Has $2.93 Million Stake in Codexis, Inc. (NASDAQ:CDXS)

Federated Hermes Inc. lowered its stake in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 14.9% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,087,951 shares of the biotechnology company's stock after selling 190,175 shares during the period. Federated Hermes Inc. owned approximately 1.31% of Codexis worth $2,927,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Summit Investment Advisors Inc. increased its stake in Codexis by 81.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 3,783 shares during the period. Wolverine Trading LLC bought a new stake in Codexis during the fourth quarter worth about $56,000. Fiduciary Trust Co bought a new stake in Codexis during the fourth quarter worth about $65,000. Group One Trading LLC bought a new stake in Codexis during the fourth quarter worth about $73,000. Finally, ProShare Advisors LLC grew its stake in Codexis by 101.1% during the fourth quarter. ProShare Advisors LLC now owns 26,543 shares of the biotechnology company's stock worth $127,000 after buying an additional 13,344 shares during the last quarter. Institutional investors and hedge funds own 78.54% of the company's stock.

Codexis Price Performance

Shares of CDXS traded down $0.05 during mid-day trading on Friday, hitting $2.74. 411,335 shares of the company traded hands, compared to its average volume of 853,431. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08. The company has a current ratio of 3.72, a quick ratio of 3.64 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average of $2.64 and a 200 day moving average of $2.90. The stock has a market capitalization of $226.59 million, a price-to-earnings ratio of -2.76 and a beta of 2.54.

Codexis (NASDAQ:CDXS - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). Codexis had a negative net margin of 149.47% and a negative return on equity of 118.47%. The company had revenue of $7.54 million for the quarter, compared to the consensus estimate of $10.38 million. As a group, equities analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Codexis to a "sell" rating in a research note on Friday, May 16th.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.